Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-Current Deffered Revenue: 2019-2023

Historic Non-Current Deffered Revenue for Kymera Therapeutics (KYMR) over the last 5 years, with Dec 2023 value amounting to $16.8 million.

  • Kymera Therapeutics' Non-Current Deffered Revenue was N/A to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year change of. This contributed to the annual value of $16.8 million for FY2023, which is 40.11% down from last year.
  • Kymera Therapeutics' Non-Current Deffered Revenue amounted to $16.8 million in FY2023, which was down 40.11% from $28.0 million recorded in FY2022.
  • Kymera Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $77.8 million during FY2020, with a 5-year trough of $16.8 million in FY2023.
  • For the 3-year period, Kymera Therapeutics' Non-Current Deffered Revenue averaged around $28.0 million, with its median value being $28.0 million (2022).
  • As far as peak fluctuations go, Kymera Therapeutics' Non-Current Deffered Revenue surged by 162.59% in 2020, and later slumped by 49.52% in 2021.
  • Over the past 5 years, Kymera Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $29.6 million in 2019, then soared by 162.59% to $77.8 million in 2020, then slumped by 49.52% to $39.3 million in 2021, then decreased by 28.74% to $28.0 million in 2022, then plummeted by 40.11% to $16.8 million in 2023.